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ABSTRACT 
Background: Latent Cytomegalovirus (CMV) infections may be reactive in consequence of immunosuppression. Recently, 
CMV-associated uveitis cases have also been reported in immunocompetent individuals. Aim: The aim of this study was to 
obtain epidemiological data by evaluating CMV DNA PCR results, clinical characteristics and risk factors of patients 
diagnosed with viral uveitis. Methods: Between the years 2011-2017, anterior chamber fluid samples of 35 patients with viral 
uveitis sent from the ophthalmology clinic to the Virology Laboratory were included in this study. CMV DNA real-time PCR 
results were evaluated. Results: CMV DNA positivity was detected in 9 (26%) of the 35 patients. CMV DNA positivity was 
highest (13%) in over 60 years (p=0.02). Acute recurrent uveitis in 44% (4/9) of patients, single eye involvement in 78% (7/9) 
and anterior uveitis in 44% (4/9) were found. Conclusion: In this study, CMV DNA positivity was detected in 26% of the 
patients with viral uveitis. Considering the presentations of a small number of cases related to CMV uveitis in our country, this 
study is important due to being the most comprehensive study in our country. 
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ytomegalovirus (CMV) is double-stranded DNA 
virus which belongs to the Beta herpes virinae 
subfamily and Herpes viridae family [1,2]. The 
worldwide prevalence of CMV infection is close to 60% in 
developed countries and 100% in developing countries [3, 
4]. Following primary infection, CMV remaining latent in 
myeloid progenitor cells may cause anterior uveitis, which 
is the most common form of inflammation in the eye, by 
reactivation in patients receiving transplantation, AIDS, or 
immunosuppressive therapy [1-3]. Advanced age, diabetes 
mellitus, malignancy, autoimmune disease, inherited and / 
or acquired immunodeficiency disorders not associated 
with HIV are also risk factors. On the other hand, CMV 
anterior uveitis infection can also occur in 
immunocompetent patients.  
Recently, case reports related to this issue have 
increased [4-6]. Epidemiology of infectious uveitis 
presents changes in geographical and climatic conditions, 
differences depending on the factors of the host [4-6]. 
Infectious uveitis accounts for 13% - 21% of uveitis cases 
in developed countries [7-9]. Infections are estimated to be 
mostly linked to herpes viruses and these viruses are 
among the important pathogens of the anterior and 
posterior uveitis. In developing countries, infectious 
etiology is responsible for 50% of uveitis. Tuberculosis, 
oncocerciasis, cysticercosis, leprosy and leptospirosis are 
thought to play a role especially in toxoplasmosis [15].  
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 CMV can cause acute, recurrent, hypertensive or 
chronic anterior uveitis [16-18]. Acute uveitis is seen 
mostly in the ages between 20-50, and chronic uveitis in 
the age group of 40-70. Ocular involvement is often 
unilateral and seen in males [16, 17]. Laboratory tests are 
important because of the discrimination of infectious and 
non-infectious uveitis and the difficulties in identifying 
viral etiologic agents [19]. 
 For the diagnosis of CMV uveitis, CMV serology may 
be useful to exclude viral etiology. Accompanying CMV 
IgM positivity in patients with CMV IgG positive indicates 
active systemic infection but does not prove ocular 
infection [16].
 
In large epidemiological studies on uveitis, 
48% of the cases etiology is not found, but viruses are 
increasingly important in the anterior uveitis etiology with 
the developments in molecular diagnostic techniques [7]. 
CMV uveitis can be diagnosed by PCR detection of viral 
DNA in intraocular fluid samples or by Goldmann-Witmer 
analysis of anti-viral antibodies [19]. One of these tests is 
preferred depending on the immune status of the patient, 
the time of sampling, and the presence of acute or chronic 
uveitis.  However, so there are studies suggesting that both 
tests should be done if possible [20]. 
In addition, identification of the "owl eye" morphology 
specific to CMV in infected cells using confocal 
microscopy is helpful for diagnosis [10]. PCR analysis of 
current intraocular fluid specimens is the most commonly 
used method to confirm the clinical diagnosis before the 
onset of treatment, when acute CMV uveitis is suspected 
[22]. It is very useful in terms of rapid detection and 
effective treatment of viral pathogen [11]. Systemic or 
local ganciclovir or both in combination or systemic 
valganciclovir may be used in the treatment of CMV 
uveitis. Since neutropenia is an important complication of 
valganciclovir therapy, valaciclovir is considered a 
promising option for preventing CMV relapses. The 
duration of treatment has not been known yet [10,12]. 
Therefore this study was designed to obtain 
epidemiological data by evaluating retrospectively PCR 
results of CMV DNA, clinical characteristics and risk 
factors of patients. 
MATERIAL AND METHODS 
Between the years 2011-2017, anterior chamber fluid 
samples of 35 patients diagnosed with viral uveitis sent 
from the ophthalmology clinic to the Istanbul University, 
Istanbul Faculty of Medicine, Department of Medical 
Microbiology, Virology Laboratory were included in this 
study. CMV DNA real-time PCR results were evaluated 
retrospectively. The study data were assessed using the 
patient files of the Clinic in Ophthalmology together with 
the laboratory patient files and the laboratory operating 
system. This present study was approved by Ethics 
Committee of Istanbul University, Istanbul Faculty of 
Medicine and adhered to the Declaration of Helsinki. 
Viral DNA extraction and PCR analysis were 
performed using with AmpliPrep / COBAS TaqMan (CAP 
/ CTM) 96 (Roche Diagnostics GmbH, Mannheim, 
Germany) for CMV DNA determination in anterior 
chamber fluid samples. The extracted viral nucleic acid 
product was transferred to the Cobas TaqMan 96 PCR unit 
automatically and amplified by PCR method with the 
AmpliPrep / Cobas CMV test (CAP / CPM) kit. In the 
software program, the test results of the studied samples 
were evaluated qualitatively.  
Data analysis was performed by using SPSS 21 (SPSS 
Inc, Chicago, IL, USA) program. The normal distribution 
suitability of the variables was examined by visual 
methods (histogram and probability plots) and 
Kolmogorov-Smirnov test. Mean age between genders was 
compared using Student's t test, age groups and gender 
using CMV DNA positivity Fisher's test. p values below 
0.05 were considered statistically significant.  
RESULTS 
The mean age of the 35 patients being included in the 
study and having ranging in age from 9 to 81 was 45.46 ± 
15.56, 66% male (95% confidence interval [CI] 14-42) and 
34% (95% CI 21-51) female patients. The mean age of 
male patients was 46.04 ± 14.62, while the mean age of 
female patients was 44.33 ± 17.84. There was no 
statistically significant difference between the genders in 
terms of age averages (p= 0.76). CMV DNA positivity was 
examined according to age groups and it was found to be 
higher than other age groups by 14% over 60 years old and 
statistically significant (p= 0.02). Distribution of patients 
diagnosed with CMV uveitis according to age groups and 
gender is showed in Figure 1. 
CMV DNA was positively detected in 9 out of the 35 
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patients (26%), (95% CI 14-42), included in the study. The 
patients with CMV DNA detected in the anterior chamber 
fluid were 5 male and 4 female patients and their median 
age was 63 (range 9-78). There was no significant 
difference in CMV DNA positivity between gender (p= 
0.69).  
 
Figure 1. Distribution of patients diagnosed with CMV 
uveitis according to age groups and gender 
Acute uveitis was found in 33% (3/9) of patients, acute 
recurrence in 44% (4/9) and chronic uveitis in 9% (1/9).  
In 44% (4/9) of cases anterior uveitis and 78% (7/9) of 
cases had unilateral involvement.  Clinical findings, 
comorbid diseases and immunosuppressive drug use of 
CMV uveitis-diagnosed patients are shown in Table 1. 
Three of the nine patients with CMV DNA positive (one 
female, two male) did not have comorbid disease. The 
history of inhaled steroid use was detected for two patients 
due to their bronchial asthma. In one patient, ocular trauma 
was not detected except intraocular steroid injection. In 
patients, anti-HIV positivity was not detected. 
DISCUSSION 
Members of the herpes virus family that cause latent 
infections may show reactivation due to many risk factors. 
This explains the basic pathological mechanism in various 
diseases including uveitis [16].  In this study, the results of 
patients who detected CMV DNA positivity by PCR 
method in intraocular fluid sent to Virology Laboratory 
with viral uveitis diagnosis within six years period were 
examined. Epidemiological features of the disease were 
also evaluated with our laboratory findings. 
Table 1 - Clinical findings, comorbid diseases and immunosuppressive drug use histories of patients with CMV uveitis 
Patient/ 
Gender/Age 
Course of uveitis Laterality Localization Comorbidity Trauma İmmunsuppressive 
medication use 
1/M/66 Chronic  Unilateral Unknown DM, NHL, CRD None None 
2/F/44 Acute recurrence Unilateral Anterior None None  None 
3/F/27 Acute recurrence Unilateral Anterior Asthma, 
Behçet disease 
None Inhaled steroid 
4/F/9 
 
Unknown Bilateral Posterior  PIDD None None 
5/M/38 Acute recurrence Unilateral Anterior None  None None 
6/F/64 Acute Unilateral Posterior Behçet disease 
ALL 
None Chemotherapy 
7/M/78 Acute Unilateral Posterior Asthma IO steroid 
injection 
Inhaled steroid 
8/F/66 Acute recurrence Unilateral Anterior None None None 
9/F/63 Acute Bilateral Posterior CLL,DM None Chemotherapy 
DM: Diabetes mellitus; NHL: Non-Hodgkin lymphoma; CRD: Chronic renal disease; PIDD: Primary immune deficiency 
disease; ALL: Acute lymphoblastic leukemia; CLL: Chronic lymphocytic leukemia, IO: Intra ocular 
CMV DNA positivity in intraocular fluid was found as 
26% (9/35). CMV anterior uveitis cases are reported all 
over the world. When the CMV anterior uveits 
seroprevalance studies were examined, the rates of CMV  
 
DNA positivity were reported as 1%, 1.7%, 13.3% and 
71.4% in a small number of studies reported in European 
countries [25-28]. In a study conducted in Turkey only 
four of the 51 patients diagnosed with viral uveitis, CMV 
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DNA was detected by PCR method [13]. 
Other studies were limited to a few case reports. In 
Asian countries, CMV positivity was reported in patients 
with uveitis between 1.68-12.7% and in the USA 0.8% 
[30-35]. The seroprevalence of CMV infection varies 
among continents in the world. It is about 69.1% to 98.6% 
in Asia, while it varies from 41.9% to 57% in Western 
countries [17]. More cases of CMV were reported in Asian 
countries than in Western countries. Thus, CMV can be 
attributed to differences in variable rates and geographical 
distribution of seroprevalence.  
Sugita et al [22] found that sensitivity, specificity, 
positive predictive value (PPV) and negative predictive 
value (NPV) of PCR results for infectious ocular diseases 
were 91.3%, 98.8%, 98.5%, 92.4% respectively and 
reported that PCR is a reliable method for excluding 
infectious agents.  Kharel et al [36]
 
reported sensitivity, 
specificity, PPD and NPD values of CMV PCR as 100%, 
71%, 15.4% and 100%, respectively. In other studies, it 
has been reported that the sensitivity of PCR method is 
80.9-90% and the specificity is 95-100% for HSV, VZV 
and CMV [37, 38]. When the PCR method is used for 
ocular fluids, it is reported that the false positive rate is 
very low. Whereas false positive results may be due to 
contamination, false negative results might result from 
polymorphism, sample impairment or sample taken during 
the acute phase of the disease. Positive PCR results 
confirm the diagnosis of infection, but negative PCR 
results do not exclude viral infections [7, 39]. 
In this study, median age of patients with CMV DNA 
positivity in intraocular fluid was 63. In other studies 
conducted in this regard, in a study involving Belgium and 
the Netherlands, the mean age of CMV DNA-positive 
patients was 38.57±12.11, 55.2±18.6 in Spain, and 47.5± 
14.8 in Korea [3, 28, 40]. The mean age in this study was 
found to be higher when compared to the results of other 
studies, besides found to be consistent with the literature. 
In this study, when the distributions according to age 
groups were examined, the intraocular CMV DNA 
positivity was found to be higher than the other groups 
with 14% over 60 years old and statistically significant (p= 
0.02). In a study evaluating the distribution of CMV 
uveitis by age groups in Vietnam, it was found to be 6% 
between the age of 21-40 years, 4.1% between the age of 
41-60 years and 3.7% the age of over 60 years and there 
was no found significant difference between the age 
groups in terms of the frequency of CMV uveitis [33]. 
CMV uveitis has been reported to be seen at all ages. 
Nevertheless, acute recurrent anterior uveitis, the most 
commonly described clinical manifestation of CMV 
uveitis, is reported to be more frequent in the third and 
fifth decades of life [10]. In this study, CMV uveitis was 
found to be more common in male patients. However, the 
difference was not statistically significant. In other studies, 
similar to this study, is generally reported male 
predominance [3, 28, 30, 35]. There are also studies 
reporting that CMV uveitis is seen more frequently in 
female patients, but these studies are quite limited [33]. 
The cause of the more frequent occurrence in male patients 
is unknown.   
CMV has been reported to be an anterior uveitis, with 
the most common form of inflammation in the eye [5-7]. 
However, in this study, only anterior uveitis due to CMV 
was detected in 44% of the patients. We think that these 
results can be caused by the fact that the smaller sample 
size compared to other studies. In this study, four patients 
were diagnosed with posterior uveitis. These four patients 
also had comorbid disease supporting immunosuppression 
(Table 1). Contrary to isolated anterior uveitis, CMV-
associated retinitis has been reported to occur in 
immunocompromised individuals [37]. In this study, 
comorbid disease was not detected in only three of nine 
patients with CMV DNA positive in the intraocular fluid. 
Concomitant comorbid disease in one of the cases was 
non-Hodgkin lymphoma (NHL). In the literature, there are 
only one case reports of CMV retinitis receiving 
chemotherapy after NHL diagnosis [41, 42]. In a study 
involving 18 patients with CMV-positive, posterior uveitis 
and panuveitis, comorbid diseases such as 
immunosuppressive drug use (hematologic malignancies, 
systemic autoimmune diseases and organ transplantation), 
NHL, primer immunodeficiency, diabetes mellitus were 
reported in patients [43].  
In this study, similar comorbid diseases were detected 
in the patients with CMV uveitis. Although CMV uveitis is 
a defined disease in the immunocompromised host, the 
number of anterior uveitis cases in immunocompetent 
patients is increasing steadily [6, 34]. This increase can be 
explained by the development of diagnostic techniques and 
the increased use of highly sensitive molecular methods 
[21]. A very few case reports of CMV uveitis in 
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immunocompetent patients in our country are reported 
[29].
  
CONCLUSION 
CMV DNA positivity was found in 26% of patients 
diagnosed as having viral uveitis in this study. In Turkey, 
when considering the limited number of case reports, it is 
the most comprehensive study of the CMV uveitis. These 
case reports do not provide sufficient data for the 
epidemiology of CMV uveitis infection. We believe that 
our study will lead to similar studies. 
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